CCRN

CCRN is a healthcare-staffing business unwinding a COVID-era boom: revenue has fallen four straight years from the $2.80B FY2022 peak to $1.05B in FY2025 (-21.6% YoY), driven by volume declines in Nurse & Allied and Physician Staffing per the MD&A. The FY2025 net loss of -$94.9M looks alarming (ROE -29.4%, diluted EPS -$2.93), but it is dominated by non-cash and one-time items management calls out: a $77.9M goodwill impairment (triggered by the Q4 drop in the company's own market cap), a $29.6M deferred-tax valuation allowance, and $6.0M of CEO-transition severance. Strip those and the underlying business is near operating breakeven, and it still generated $48.3M of operating cash flow — so the reported loss overstates the operational deterioration.

The balance sheet is the reason this is a hold rather than a sell. Equity is $323M against just $126M of total liabilities (0.39x liabilities/equity), cash grew 33% to $109M (~$3.37/share, a quarter of the market cap), there were no ABL borrowings at year-end with ~$96M of net availability, and the company even collected a $20M termination fee after Aya walked away from the December-2024 merger. This is a financially durable company trading at 0.4x sales and roughly 1.3x book — the market is pricing in continued decline, which caps downside if revenue stabilizes.